Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting
-- Podium presentation of 24-week data from first cohort of the OPTIC trial at
-- Adverum to host a conference call and webcast to review the data presentation on
Podium Presentation: Interim 24-week Data from the OPTIC Trial: Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 (AAV.7m8-aflibercept) for Neovascular (Wet) Age-related Macular Degeneration
Time: 7:41 –
Speaker: Szilard Kiss, M.D., director of clinical research in the
Adverum plans to issue a press release simultaneously with the presentation of the 24-week data from the first cohort of patients (n=6) in the OPTIC trial.
Conference Call and Webcast
Adverum will host a conference call and webcast to review the data presented on
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.
Investor and Media Inquiries: Investors:
Myesha LacyVice President, Investor Relations and Corporate Communications firstname.lastname@example.org 650-304-3892 Media: Joshua R. MansbachSolebury Trout email@example.com 646-378-2964
Source: Adverum Biotechnologies, Inc.